Skip to main content
SCYX logo

SCYNEXIS, Inc. (SCYX) Stock Price & Analysis

SCYNEXIS, Inc. (SCYX) — MoonshotScore 23/100 (Weak band), calculated Nov 18, 2026. Price $2.60 (-7.62%), as of the Nov 19, 2026 trading session; market cap $25.9M.

Educational signal · not a buy or sell recommendation · How to read this

$2.60 −$0.215 (-7.62%) Market Cap $25.9M

SCYNEXIS, Inc. · SCYX · NASDAQ

SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing novel treatments for fungal infections. Their primary product is BREXAFEMME, an oral tablet for vulvovaginal candidiasis (VVC).

Price as of Nov 19, 2026

Key Statistics

23 of 100

MoonshotScore v2 · SCYNEXIS (SCYX)

Weak
Business Quality Thin (35)
Financial Safety Okay (52)
Valuation Fair (75)
Growth Durability Growing (74)
Momentum Slipping (31)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but weak quality. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Slipping.

  • quarterly revenue $235,000 (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 5 of the last 8 reports
  • Altman Z -6.63 · Piotroski F 2

Holding back: weak price trend

Helping: an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SCYX (57 recorded, newest six shown)
RecordedScoreBand
23Weak
27Weak
27Weak
27Weak
23Weak
23Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.60
Change on the day-7.62%
52-week range$2.60 – $9.12
Market capitalisation$25.9M—
Shares traded on the day108.4K

Price & events

Other perspectives

Council score for SCYNEXIS (SCYX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Weak

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is SCYNEXIS (SCYX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. SCYNEXIS, Inc. (SCYX) is listed on NASDAQ. It employs 18 people and is led by David Angulo. In Q2 FY2026 it reported revenue of $235,000 and net income of $7M. The market values it at $25.9M.

2 · Latest results

What do the latest results show for SCYNEXIS (SCYX)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $235,000. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$235,000$7M$0.63 (diluted)
Q4 FY2025$19M$12M$2.25 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for SCYNEXIS (SCYX)?

Short answer · as of

The MoonshotScore pillars rate an attractive price, durable growth as strengths. What is holding it back is weak price trend. The distress and quality screens read Altman Z -6.63 · Piotroski F 2. Trailing ratios: ROE -18.7% · ROA -14.9% · current ratio 7.57 · earnings yield -26.6% · free-cash-flow yield -59.7%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -6.63 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-18.7%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does SCYNEXIS compare with its peers?

Short answer

SCYNEXIS's score ranks tied for 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
BeOne Medicines Ltd. (ONC) Same industry, near in market value$403.60 Nov 18, 2026$46.1B96 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Pfizer Inc. (PFE) Named competitor$28.06 Nov 18, 2026$160B67 5-pillar Nov 18, 2026
Cullinan Therapeutics, Inc. (CGEM) Same industry, near in market value$9.07 Nov 19, 2026$589M51 5-pillar Nov 18, 2026
Galecto, Inc. (DMRA) Same industry, near in market value$24.30 Nov 19, 2026$1.50B50 5-pillar Nov 18, 2026
111, Inc. (YI) Same industry, near in market value$2.51 Nov 19, 2026$22.1M40 5-pillar Nov 18, 2026
High Tide Inc. (HITI) Same industry, near in market value$2.29 Nov 19, 2026$204M36 5-pillar Nov 18, 2026
Kyntra Bio, Inc. (KYNB) Same industry, near in market value$1.83 Nov 19, 2026$7.41M32 5-pillar Nov 18, 2026
Satellos Bioscience Inc. Common Stock (MSLE) Same industry, near in market value$5.80 Nov 19, 2026$123M32 5-pillar Nov 18, 2026
Rein Therapeutics, Inc. (RNTX) Same industry, near in market value$0.37 Nov 19, 2026$31.7M30 5-pillar Nov 18, 2026
PetMed Express, Inc. (PETS) Same industry, near in market value$0.90 Nov 18, 2026$20.0M29 5-pillar Nov 18, 2026
SCYNEXIS (SCYX) — this page$2.60$25.9M23
LifeMD, Inc. (LFMD) Same industry, near in market value$1.59 Nov 19, 2026$77.1M23 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 18, 2026

Transactions
13
Identified insiders
7
Purchases
0
Sales
0
Other transactions
13

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SCYX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SCYX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About SCYNEXIS (SCYX)

These answers are editorial: 1 of these 9 answers is drawn from the SCYX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SCYX?

SCYX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing novel treatments for fungal infections.

Is SCYX a good stock to buy?

Stock Expert AI does not rate SCYX buy, sell or hold. SCYNEXIS, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SCYX stock price today?

The last price recorded for SCYNEXIS, Inc. (SCYX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does SCYNEXIS, Inc. manage patent expiration risks?

SCYNEXIS, Inc. manages patent expiration risks through a multi-faceted approach. This includes actively pursuing patent extensions and developing new formulations of its existing drugs to extend their market exclusivity.

What are the key factors to evaluate for SCYX?

SCYNEXIS, Inc. (SCYX) holds a MoonshotScore in the low range. The global antifungal market is growing, and expanding into these regions could provide a significant revenue boost. Not financial advice.

How frequently does SCYX data refresh on this page?

SCYX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SCYX's recent stock price performance?

SCYNEXIS, Inc. (SCYX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel antifungal agent (ibrexafungerp) with a unique mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SCYX overvalued or undervalued right now?

SCYNEXIS, Inc. (SCYX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of SCYX?

Fractional-share availability for SCYNEXIS, Inc. (SCYX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.